1. Home
  2. BTAI vs NEHC Comparison

BTAI vs NEHC Comparison

Compare BTAI & NEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTAI
  • NEHC
  • Stock Information
  • Founded
  • BTAI 2017
  • NEHC 2023
  • Country
  • BTAI United States
  • NEHC United States
  • Employees
  • BTAI N/A
  • NEHC N/A
  • Industry
  • BTAI Biotechnology: Pharmaceutical Preparations
  • NEHC
  • Sector
  • BTAI Health Care
  • NEHC
  • Exchange
  • BTAI Nasdaq
  • NEHC NYSE
  • Market Cap
  • BTAI 8.3M
  • NEHC 7.5M
  • IPO Year
  • BTAI 2018
  • NEHC N/A
  • Fundamental
  • Price
  • BTAI $1.84
  • NEHC $0.51
  • Analyst Decision
  • BTAI Buy
  • NEHC
  • Analyst Count
  • BTAI 5
  • NEHC 0
  • Target Price
  • BTAI $34.60
  • NEHC N/A
  • AVG Volume (30 Days)
  • BTAI 294.8K
  • NEHC 14.7M
  • Earning Date
  • BTAI 08-05-2025
  • NEHC 01-01-0001
  • Dividend Yield
  • BTAI N/A
  • NEHC N/A
  • EPS Growth
  • BTAI N/A
  • NEHC N/A
  • EPS
  • BTAI N/A
  • NEHC N/A
  • Revenue
  • BTAI $1,852,000.00
  • NEHC $530,024.00
  • Revenue This Year
  • BTAI $5.03
  • NEHC N/A
  • Revenue Next Year
  • BTAI $291.01
  • NEHC N/A
  • P/E Ratio
  • BTAI N/A
  • NEHC N/A
  • Revenue Growth
  • BTAI 5.47
  • NEHC N/A
  • 52 Week Low
  • BTAI $1.17
  • NEHC $0.47
  • 52 Week High
  • BTAI $23.04
  • NEHC $12.29
  • Technical
  • Relative Strength Index (RSI)
  • BTAI 62.90
  • NEHC N/A
  • Support Level
  • BTAI $1.59
  • NEHC N/A
  • Resistance Level
  • BTAI $2.22
  • NEHC N/A
  • Average True Range (ATR)
  • BTAI 0.21
  • NEHC 0.00
  • MACD
  • BTAI 0.04
  • NEHC 0.00
  • Stochastic Oscillator
  • BTAI 75.00
  • NEHC 0.00

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About NEHC NEW ERA HELIUM INC

New Era Helium Inc. is an exploration and production company that sources helium produced in association with the production of natural gas reserves in North America. The Company's primary operations include the exploration, development and production of helium, natural gas, oil and natural gas liquids. The Company owns and operates over 137,000 acres in Southeast New Mexico and has over 1.5 billion cubic feet of proved and probable helium reserves. Its producing oil and gas assets and non-producing acreage are located in Chaves County, New Mexico.

Share on Social Networks: